CORONA Remedies FY26 Revenue Up 17% to ₹1,403 Crore; PAT Jumps 33% & Dividend of ₹210/Share
CORONA Remedies reported a 17% increase in FY26 revenue to ₹1,403 crore and a 33% rise in PAT. The company declared a dividend of ₹210 per share. Two brands surpassed ₹100 crore in revenue. Strategic acquisitions, including Wokadine, and biosimilar launches contributed to growth. CORONA expects 15% revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27 too. The company is undertaking the expansion of its manufacturing capabilities through the addition of a new 600-kg line expansion, alongside the commissioning of our dedicated hormone manufacturing plant, which is expected to become operational in Q1 or Q2 of FY27.
The announcement includes significant financial growth, strategic acquisitions, and expansion plans, which are likely to have a substantial positive impact on the company's future performance and market position.
The announcement highlights strong financial performance, including revenue and profit growth, dividend declaration, and strategic acquisitions, all indicating positive developments for the company.
CORONA Remedies Limited announced its Q4 and FY26 financial results in a conference call held on May 12, 2026. The company's revenue for FY26 grew by 17% to ₹1,403 crore compared to ₹1,106 crore in FY25, while Profit After Tax (PAT) increased by 33%. The company outperformed industry growth, achieving nearly 2x the industry rate. Two of CORONA's brands have surpassed the ₹100 crore revenue milestone. The company has declared a 100% dividend, which is ₹210 per share for FY26. 20% PAT growth is expected in FY27. 80% gross margins are expected in the coming years. 15% revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27 too. The company expects to sustain 15% plus revenue growth organically and 25% revenue growth in acquired brand with 20% plus PAT growth in FY27 too. The company is undertaking the expansion of its manufacturing capabilities through the addition of a new 600-kg line expansion, alongside the commissioning of our dedicated hormone manufacturing plant, which is expected to become operational in Q1 or Q2 of FY27.
Nirav Mehta, Managing Director and CEO, highlighted that CORONA continues to be the fastest-growing pharmaceutical company among the top 30 companies in IPM, improving its ranking to 27th position. The company has successfully completed two strategic acquisitions in FY26: Wokadine and the Bayers Portfolio. Additionally, CORONA has entered the biosimilars and biologics market with the launch of three biosimilar products in FY26. The company's strategy includes increasing market share in key therapeutic areas and driving growth through new product launches and acquisitions. The expansion of manufacturing capabilities and the receipt of EAEU GMP certification will support domestic and international business growth.
Bhavin Bhagat, CFO, detailed the financial performance, noting that Q4FY26 revenue stood at ₹353 crore, a 20.2% year-on-year growth. EBITDA for FY26 grew by 22.3% to ₹293 crore, with margins improving by 80bps to 20.9%. The company's cash flow from operations stood at ₹229 crore. For FY27, the company is comfortable with the existing MR strength. As far as the borrowings are concerned, if you can see in FY 126, it is reflected as ₹143 crore in the form of borrowings. INR 142.9 crore borrowings is only because of the overdraft or majorly because of the overdraft on the basis of FDs which we have. So, we have FDs on the asset side and we have overdraft from the liability side in the form of borrowings.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.